In this month’s issue, we look into the future of two indications with high unmet need – amyotrophic lateral sclerosis (ALS) and nonalcoholic steatohepatitis (NASH)– through the lens of medical tech advances that aim to improve patients’ quality of life or accelerate the development of therapies via a less cumbersome method of diagnosis.

On the occasion of World IVF day, in another forward-looking analysis, we examine the assisted reproductive tech sector and the investment opportunities it presents.

Also in this issue, we dive into the latest trends in medical applications of nanotechnology.

Elsewhere, coinciding with the World Health Organization’s recent declaration of monkeypox as a global health emergency, we discuss new tests in development and how increased surveillance may drive this market. In a comment piece, Matt Barnes shares his vision for an IT network architecture fit for the NHS’ digital journey.

Read the latest issue of Medical Technology for all this and more news, insights, data and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a https://medical-technology.nridigital.com/medical_technology_aug22/issue_53new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.